Lupus & antiphospholipid syndrome
Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis
Authors' conclusion
In this NMA, anifrolumab and belimumab achieved similar SRI-4 responses.
Study context
- Population
- Adult patients with SLE in randomized controlled trials (RCTs)
- Participants
- 8,607 patients11 trials
- Comparison
- Belimumab or anifrolumab plus standard of care vs placebo plus standard of care
- Outcome
- SRI-4 response
Methodological detailsRoB 2, GRADE (CINeMA)
- RoB 2
- GRADE (CINeMA)
Pooled result
As reported in the abstract
Each group vs placeboOdds ratio (95% CI)
Anifrolumab
1.78(1.41–2.24)
Belimumab
1.62(1.38–1.90)
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| BICLA responseAnifrolumabvs BelimumabBelimumab BICLA data derived from post hoc analyses | 1.56 (1.10–2.21) | |
| 0.512Odds ratio (log scale) |
BILAG organ-domain responses
- Mucocutaneous and musculoskeletal responses favored both biologics vs placebo
- Renal and cardiovascular/respiratory effects not statistically significantly different
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Herpes zosterAnifrolumabvs Belimumab | 4.74 (2.00–11.21) | |
| 0.050.21520Odds ratio (log scale) |
SAEs and serious infections
- Similar between biologics
Original publication
Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis. Semin Arthritis Rheum. Published 9 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →